Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 1b Trial of FB102 Demonstrates Significant Facial Repigmentation and Sustained Vitiligo Response
2
Higher Cumulative Isotretinoin Dose May Reduce Acne Relapse
3
Breakout Bulletin: July 6-July 10
4
First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo
5